Dose rationale and pharmacokinetics of dexmedetomidine in mechanically ventilated new-borns: impact of design optimisation.

Purpose: There is a need for alternative analgosedatives such as dexmedetomidine in neonates. Given the ethical and practical difficulties, protocol design for clinical trials in neonates should be carefully considered before implementation. Our objective was to identify a protocol design suitable f...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Clinical Pharmacology Vol. 75; no. 10; pp. 1393 - 1405
Autores principales: van Dijkman, Sven C., De Cock, Pieter A. J. G., Smets, Koenraad, Decaluwe, Wim, Smits, Anne, Allegaert, Karel, Vande Walle, Johan, De Paepe, Peter, Della Pasqua, Oscar
Formato: equations & formulas research tables/charts Journal Article
Publicado: Springer Nature Oct2019
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=138590240&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 138590240
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00316970
        NP9
      jtl: European Journal of Clinical Pharmacology
      issn: 00316970
      maglogo: N
    pubinfo:
      dt: Oct2019
      vid: 75
      iid: 10
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        138590240
        138590240
        144102203
        138590240
        10.1007/s00228-019-02708-y
        138590240
      ppf: 1393
      ppct: 12
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Dose rationale and pharmacokinetics of dexmedetomidine in mechanically ventilated new-borns: impact of design optimisation.
      aug:
        au:
          van Dijkman, Sven C.
          De Cock, Pieter A. J. G.
          Smets, Koenraad
          Decaluwe, Wim
          Smits, Anne
          Allegaert, Karel
          Vande Walle, Johan
          De Paepe, Peter
          Della Pasqua, Oscar
        affil: Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden, The Netherlands
      sug:
        subj:
          Adrenergic alpha-Agonists Pharmacokinetics
          Adrenergic alpha-Agonists Administration and Dosage
          Respiration, Artificial In Infancy and Childhood
          Dosage Calculation
          Drug Design
          Infant, Newborn
          Individualized Medicine
          Simulations
          Metabolic Clearance Rate
          Infant, Premature
          Pilot Studies
          Human
          Infant, Newborn: birth-1 month
      ab: Purpose: There is a need for alternative analgosedatives such as dexmedetomidine in neonates. Given the ethical and practical difficulties, protocol design for clinical trials in neonates should be carefully considered before implementation. Our objective was to identify a protocol design suitable for subsequent evaluation of the dosing requirements for dexmedetomidine in mechanically ventilated neonates. Methods: A published paediatric pharmacokinetic model was used to derive the dosing regimen for dexmedetomidine in a first-in-neonate study. Optimality criteria were applied to optimise the blood sampling schedule. The impact of sampling schedule optimisation on model parameter estimation was assessed by simulation and re-estimation procedures for different simulation scenarios. The optimised schedule was then implemented in a neonatal pilot study. Results: Parameter estimates were more precise and similarly accurate in the optimised scenarios, as compared to empirical sampling (normalised root mean square error: 1673.1% vs. 13,229.4% and relative error: 46.4% vs. 9.1%). Most importantly, protocol deviations from the optimal design still allowed reasonable parameter estimation. Data analysis from the pilot group (n = 6) confirmed the adequacy of the optimised trial protocol. Dexmedetomidine pharmacokinetics in term neonates was scaled using allometry and maturation, but results showed a 20% higher clearance in this population compared to initial estimates obtained by extrapolation from a slightly older paediatric population. Clearance for a typical neonate, with a post-menstrual age (PMA) of 40 weeks and weight 3.4 kg, was 2.92 L/h. Extension of the study with 11 additional subjects showed a further increased clearance in pre-term subjects with lower PMA. Conclusions: The use of optimal design in conjunction with simulation scenarios improved the accuracy and precision of the estimates of the parameters of interest, taking into account protocol deviations, which are often unavoidable in this event-prone population.
      pubtype: Academic Journal
      doctype:
        equations & formulas
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N